Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615988 · ClinicalTrials.gov registry record
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
A clinical trial of Cancer and Thyroid, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT04615988 is a study of Cancer and Thyroid that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 16 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04615988, a study of Cancer and Thyroid, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed death ligand-1 (PD-L1). Immunotherapy is treatment that makes changes to the immune system to try to fight cancer. Immunotherapy treatments that block the activity of important parts of the immune system called PD-1 and PD-L1 are used to standardly treat many different types of cancer and can cause thyroid toxicity in certain people. In this study the treatment for your cancer is not research treatment but standard of care determined by your oncologist. Blood will be drawn before starting treatment to determine the amount of Vitamin D and also to assess thyroid function. Also questionnaires will be completed before starting treatment and while on treatment to assess symptoms you are experiencing.
Interventions
- OTHER blood draw and questionnaire completion
- OTHER questionnaire completion, blood collection
Study Locations (1)
New York
- Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04615988
The ClinicalTrials.gov registry entry for NCT04615988 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which blood draw and questionnaire completion is the first listed.
NCT04615988 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04615988 about?
NCT04615988 is a clinical study titled "Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors". The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed death ligand-1 (PD-L1). Immunot...
What is the current status of trial NCT04615988?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2021-06-09. Estimated completion is 2027-06.
What conditions does trial NCT04615988 study?
This clinical trial studies the following conditions: Cancer, Thyroid, PD-1.
What interventions are being tested in trial NCT04615988?
The interventions under investigation include: blood draw and questionnaire completion (OTHER), questionnaire completion, blood collection (OTHER).
Who is sponsoring clinical trial NCT04615988?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04615988 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.